Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 173 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EPOCH-R Clear all
Completed Phase 2 Interventional Results available

Crossover Trial of AD109 in Obstructive Sleep Apnea

NCT04580394
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test
Drug · Diagnostic Test
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 27, 2026, 1:34 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

NCT02700022
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Duarte, California • Chapel Hills, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Not applicable Interventional Results available

Use of Amplification in Children With Unilateral Hearing Loss

NCT02269124
View directory record Official record
Conditions
Unilateral Hearing Loss
Interventions
Hearing aid
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
6 Years to 12 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00032019
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
80
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 27, 2026, 1:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intranasal Insulin for Treatment of Alcohol Use Disorder

NCT05988632
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Not applicable Interventional

Dietary Supplementation in Heart Failure

NCT03980574
View directory record Official record
Conditions
Heart Failure
Interventions
R Drink
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)

NCT00685126
View directory record Official record
Conditions
Reactive Airways Disease (RAD)
Interventions
Levalbuterol HCl Inhalation Solution, Albuterol HCl Inhalation Solution
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Up to 48 Months
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
32
States / cities
Little Rock, Arkansas • Corona, California • Englewood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

NCT03429543
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin, Insulin, Placebo, Linagliptin, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00118209
View directory record Official record
Conditions
Large B Cell Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, filgrastim, pegfilgrastim
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
47
States / cities
La Jolla, California • Mountain View, California • Palo Alto, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

SNIFF Multi-Device Study 2

NCT04199767
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Impairment
Interventions
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 27, 2026, 1:34 PM EDT
Terminated Phase 1 Interventional

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

NCT00973804
View directory record Official record
Conditions
Leukemia, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, MDS, Multiple Myeloma
Interventions
EPOCH-F/R, FLAG, Transplant Preparative Regimen (Flu/Cy/Mes), GVHD Prophylaxis (tacrolimus and sirolimus), Double Cord Blood Transplantation
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Results available

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

NCT02043847
View directory record Official record
Conditions
Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
Interventions
Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF), Autologous transplant
Radiation · Drug · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 27, 2026, 1:34 PM EDT
Recruiting Phase 1 Interventional

R-MVST Cells for Treatment of Viral Infections

NCT05183490
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
Interventions
Rapidly generated virus specific T (R-MVST) cells
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

NCT03467373
View directory record Official record
Conditions
B-Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of 8.5 vs 9.0 Base Curve for 1-DAY ACUVUE(r) TruEye(r) Brand Contact Lenses

NCT02537522
View directory record Official record
Conditions
Contact Lens Base Curve (BC) Fit and Comfort
Interventions
Contact Lenses with 8.5 BC, Contact Lenses with 9.0 BC
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 27, 2026, 1:34 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

NCT05114798
View directory record Official record
Conditions
Time Restricted Eating, Obesity, Weight Loss, Colorectal Cancer
Interventions
Time restricted eating, Calorie Restriction
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
45 Years to 70 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Varenicline for Methamphetamine Dependence

NCT01365819
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Not applicable Interventional

Rochester Forensic Assertive Community Treatment Model in Minnesota

NCT07592884
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Criminal Behavior
Interventions
R-FACT intervention, Standard Outpatient Treatment
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02005471
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
5
States / cities
La Jolla, California • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 27, 2026, 1:34 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484
View directory record Official record
Conditions
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
La Jolla, California • Redlands, California • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

NCT01767909
View directory record Official record
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Insulin (Humulin® R U-100), Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 27, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

NCT00676156
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 27, 2026, 1:34 PM EDT
Not yet recruiting Phase 1 Interventional

Study Of KITE-753 in R/R B-Cell ALL

NCT07674823
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
KITE-753
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 1:34 PM EDT